CatalystMarker
Sign in
← board

PFE

Pfizerdistress 3/10 · well-funded / low risk
$24.95+1%today-13% from 52w high
pfizer.com75,000 employeesFounded 1849New York, NYDrug Manufacturers - General
Rare / Genetic 1
Lead: Carcinoma
Revenue
$14451M
Liquidity
$31553M
Runway
—
Shares 1y
+0%

Price & events

-1.2% over 6M
$23.67$25.88$28.09Jan 26Apr 26Jul 26119.6Mrating: Guggenheim: Buy (2026-07-13)rating: BMO Capital: Outperform (2026-07-13)rating: B of A Securities: Neutral (2026-07-10)rating: JP Morgan: Neutral (2026-07-08)rating: Cantor Fitzgerald: Neutral (2026-07-06)rating: HSBC: Buy → Hold (2026-07-06)rating: RBC Capital: Underperform → Sector Perform (2026-06-10)rating: Citigroup: Neutral (2026-04-29)
CatalystRating changeDilutionFinancingdashed = today
+0.5%
1D
-0.8%
1W
+0.9%
1M
-4.9%
3M
-1.1%
6M
+5.2%
1Y
-3.5%
2Y
-22.7%
5Y
-10.6%
All

Overview

Market Cap
$142.17B
Enterprise Value
$201.03B
Volume
3.57M
52 Week Range
$23.29 – $28.55
Total Shares
5.70B
Float Shares
5.69B
Short %
2.87%
% Held by Insiders
0.10%
% Held by Institutions
69.45%
RVOL
0.08x
Beta
0.31

Pipeline stages · 51 programs

Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-03-31
Elranatamab, Daratumumab, Lenalidomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-10
tofacitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-04-14
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-01
Abrocitinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-05-02
Sigvotatug Vedotin, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-16
Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-06-22
SEA-CD70, azacitidine, Venetoclax
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-04
PF-07248144, Fulvestrant, Letrozole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-22
PF-06823859
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-28
Show all 51 programs · 41 more ▾
Ritlecitinib higher dose, Ritlecitinib lower dose
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-07-30
PF-07799544, PF-07799933
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-08-02
PF-08653945, PF-08653944
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-08-04
MET097
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09-21
ibuzatrelvir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-09-27
PF-08653944
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-12
PF-08634404, Chemotherapy, Nivolumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-18
disitamab vedotin, tucatinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-10-25
Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11-16
Dazukibart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-11-25
tucatinib, trastuzumab, bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-12-31
PF-08046054, Docetaxel monotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-05
ponsegromab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-17
PF-07934040
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-19
VLA15
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-01-27
PF-08049820
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-02-02
RSVpreF
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-02-24
Mervometostat (PF-06821497), Enzalutamide, Itraconazole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-20
PF-07799933, binimetinib, cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-04-23
PF-08046876
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-08
PF-08046033
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-14
PF-07868489
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07-18
PF-06835375
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-08-02
marstacimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-10
Mevrometostat, Enzalutamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-09-12
Multivalent Group B streptococcus vaccine, Infanrix hexa, Prevenar 20
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-11-06
C.difficile vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-12-11
PF-07220060, letrozole, abemaciclib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-02
Rimegepant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01-09
PF-08032562, Fulvestrant, Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-04-14
PF-06838435 (formerly SPK-9001)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-05-29
Etrasimod
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-06-16
PF-07994525, Midazolam
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-07-10
PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-09-12
PF-08052667, Sasanlimab, BCG
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-01-29
PF-06741086
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-07-31
PF-07275315 dose 1, PF-07275315-dose 2, PF-07275315-dose 3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-10-24
Osivelotor
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2030-12-30
C. difficile vaccine (previously studied formulation), C. difficile vaccine formulation 1,
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2031-06-19
Inotuzumab ozogamicin, ALLR3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2033-10-31
Testing of hepatic AAV Vector integration
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2040-02-25

Pipeline · 80 trials · 80 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-03-31
Estimated 50%
readout ~2027-05-15
Phase 2ATM-AVI, BATGram-negative Bacterial Infections—recruiting
2027-04-10
Estimated 50%
readout ~2027-05-10
Phase 1Elranatamab, IberdomideMultiple Myeloma—recruiting
2027-04-14
Estimated 50%
readout ~2027-06-28
Phase 3tofacitinibUlcerative Colitis—active not recruiting
2027-04-25
Estimated 50%
readout ~2027-06-09
Phase 2Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVIGram-negative Bacterial Infection—recruiting
2027-05-01
Estimated 50%
readout ~2027-06-15
Phase 2PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vPneumococcal Disease—active not recruiting
Show all 80 trials · 75 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2027-05-02
Estimated 50%
readout ~2027-07-16
Phase 3AbrocitinibEczema—recruiting
2027-06-16
Estimated 50%
readout ~2027-07-16
Phase 1sigvotatug vedotin, pembrolizumab, cisplatinCarcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms—recruiting
2027-06-22
Estimated 50%
readout ~2027-08-06
Phase 2Vaccine Candidate #1, Vaccine Candidate #2, Vaccine Candidate #3Healthy Adults—recruiting
2027-07-04
Estimated 50%
readout ~2027-08-03
Phase 1SEA-CD70, azacitidine, VenetoclaxMyelodysplastic Syndrome, Acute Myeloid Leukemia—recruiting
2027-07-22
Estimated 50%
readout ~2027-10-05
Phase 3PF-07248144, Fulvestrant, EverolimusBreast Cancer—recruiting
2027-07-28
Estimated 50%
readout ~2027-10-11
Phase 3PF-06823859Myositis—recruiting
2027-07-30
Estimated 50%
readout ~2027-10-13
Phase 3RitlecitinibStable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo—active not recruiting
2027-08-02
Estimated 50%
readout ~2027-09-01
Phase 1PF-07799544, PF-07799933Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)—recruiting
2027-08-04
Estimated 50%
readout ~2027-10-18
Phase 3Elranatamab, LenalidomideMultiple Myeloma—active not recruiting
2027-08-04
Estimated 50%
readout ~2027-09-18
Phase 2PF-08653945, PF-08653944Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight—recruiting
2027-09-21
Estimated 50%
readout ~2027-12-05
Phase 3MET097Obesity and Overweight—recruiting
2027-09-27
Estimated 50%
readout ~2027-12-11
Phase 3ibuzatrelvir, remdesivirCOVID-19 Infection—recruiting
2027-10-03
Estimated 50%
readout ~2027-12-17
Phase 3ibuzatrelvirCOVID-19 SARS-CoV-2 Infection—recruiting
2027-10-12
Estimated 50%
readout ~2027-12-26
Phase 3PF-08653944Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes—recruiting
2027-10-18
Estimated 50%
readout ~2027-12-02
Phase 1/2PF-08634404, IpilimumabCarcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma—recruiting
2027-10-25
Estimated 50%
readout ~2027-12-09
Phase 1/2Disitamab vedotinBreast Cancer, Breast Neoplasms—recruiting
2027-11-02
Estimated 50%
readout ~2027-12-17
Phase 1/2PF-08634404, Ipilimumab, AxitinibCarcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Advanced, Metastatic Renal Cell Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic/Advanced Renal Cell Carcinoma—recruiting
2027-11-16
Estimated 50%
readout ~2027-12-31
Phase 2Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948Heart Failure—recruiting
2027-11-25
Estimated 50%
readout ~2028-02-08
Phase 3DazukibartDermatomyositis, Polymyositis—recruiting
2027-12-02
Estimated 50%
readout ~2028-02-15
Phase 3PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)Pneumococcal Disease—recruiting
2027-12-06
Estimated 50%
readout ~2028-01-20
Phase 1/2PF-08634404, Enfortumab VedotinUrothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma—recruiting
2027-12-31
Estimated 50%
readout ~2028-03-15
Phase 3tucatinib, trastuzumab, bevacizumabColorectal Neoplasms—recruiting
2028-01-05
Estimated 50%
readout ~2028-02-04
Phase 1PF-08046054, pembrolizumabCarcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma—recruiting
2028-01-17
Estimated 50%
readout ~2028-04-01
Phase 2/3ponsegromabCachexia, Metastatic Pancreatic Ductal Adenocarcinoma—recruiting
2028-01-19
Estimated 50%
readout ~2028-02-18
Phase 1PF-07934040Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung—recruiting
2028-01-27
Estimated 50%
readout ~2028-04-11
Phase 3VLA15Lyme Borreliosis—active not recruiting
2028-02-02
Estimated 50%
readout ~2028-03-18
Phase 2PF-08049820Atopic Dermatitis, Eczema, Atopic—recruiting
2028-02-02
Estimated 50%
readout ~2028-03-03
Phase 1ponsegromabNon-small Cell Lung Cancer (NSCLC), Cachexia—not yet recruiting
2028-02-24
Estimated 50%
readout ~2028-05-09
Phase 3RSVpreFRSV Infection—recruiting
2028-03-10
Estimated 50%
readout ~2028-05-24
Phase 3PF-08046054, Docetaxel monotherapyNon-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma—recruiting
2028-03-19
Estimated 50%
readout ~2028-05-03
Phase 2PF-08634404, ChemotherapySmall Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung, Small Cell Cancer Of The Lung—recruiting
2028-04-20
Estimated 50%
readout ~2028-05-20
Phase 1Mervometostat (PF-06821497), Enzalutamide, ItraconazoleMetastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)—recruiting
2028-04-23
Estimated 50%
readout ~2028-05-23
Phase 1PF-07799933, binimetinib, cetuximabMelanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)—recruiting
2028-05-04
Estimated 50%
readout ~2028-07-18
Phase 3PF-08653944Obesity, Overweight and/or Obesity, Overweight—recruiting
2028-07-08
Estimated 50%
readout ~2028-08-07
Phase 1PF-08046876Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer—recruiting
2028-07-14
Estimated 50%
readout ~2028-08-13
Phase 1PF-08046033Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma—recruiting
2028-07-18
Estimated 50%
readout ~2028-09-01
Phase 2PF-07868489Pulmonary Hypertension—recruiting
2028-07-29
Estimated 50%
readout ~2028-09-12
Phase 2PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous—recruiting
2028-08-02
Estimated 50%
readout ~2028-09-16
Phase 2PF-06835375Primary Immune Thrombocytopenia—recruiting
2028-09-05
Estimated 50%
readout ~2028-11-19
Phase 3Sigvotatug Vedotin, PembrolizumabNon-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)—recruiting
2028-09-10
Estimated 50%
readout ~2028-11-24
Phase 3marstacimabHemophilia A, Hemophilia B—recruiting
2028-09-12
Estimated 50%
readout ~2028-11-26
Phase 3Mevrometostat, EnzalutamideMetastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate—recruiting
2028-11-06
Estimated 50%
readout ~2029-01-20
Phase 3Multivalent Group B streptococcus vaccine, Infanrix hexa, Prevenar 20Healthy—recruiting
2028-12-11
Estimated 50%
readout ~2029-02-24
Phase 3C.difficile vaccineClostridioides Difficile Associated Disease—recruiting
2028-12-30
Estimated 50%
readout ~2029-03-15
Phase 3PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)Pneumococcal Disease—recruiting
2029-01-02
Estimated 50%
readout ~2029-03-18
Phase 3PF-07220060, letrozole, abemaciclibBreast Cancer—active not recruiting
2029-01-09
Estimated 50%
readout ~2029-03-25
Phase 3Rimegepant/BHV3000Pediatric Migraine—recruiting
2029-02-27
Estimated 50%
readout ~2029-05-13
Phase 3PF-08634404, Pembrolizumab, Chemotherapy Regimen 1Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer—recruiting
2029-03-08
Estimated 50%
readout ~2029-04-22
Phase 1/2PF-08634404, Sigvotatug Vedotin, Combination Agent 1Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer—recruiting
2029-04-14
Estimated 50%
readout ~2029-05-14
Phase 1PF-08032562, Fulvestrant, CetuximabAdvanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer—recruiting
2029-05-29
Estimated 50%
readout ~2029-07-13
Phase 2PF-06838435 (formerly SPK-9001)Hemophilia B—active not recruiting
2029-06-01
Estimated 50%
readout ~2029-08-15
Phase 3PF-08634404, Pembrolizumab, Standard of Care ChemotherapyEndometrial Neoplasms, Endometrial Cancer—not yet recruiting
2029-06-05
Estimated 50%
readout ~2029-08-19
Phase 3PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)Pneumococcal Disease—recruiting
2029-06-16
Estimated 50%
readout ~2029-07-31
Phase 2EtrasimodUlcerative Colitis—recruiting
2029-06-19
Estimated 50%
readout ~2029-09-02
Phase 3EtrasimodUlcerative Colitis—active not recruiting
2029-07-10
Estimated 50%
readout ~2029-08-09
Phase 1PF-07994525, MidazolamAdvanced Malignancies, Advanced Cancer—recruiting
2029-07-13
Estimated 50%
readout ~2029-08-27
Phase 2PF-07248144, Fulvestrant, LetrozoleLocally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer—recruiting
2029-07-28
Estimated 50%
readout ~2029-09-11
Phase 2disitamab vedotin, tucatinibBreast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer—active not recruiting
2029-09-12
Estimated 50%
readout ~2029-10-12
Phase 1PF-08046050, bevacizumab, 5-Fluorouracil (5-FU)Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma—recruiting
2030-01-29
Estimated 50%
readout ~2030-02-28
Phase 1PF-08052667, Sasanlimab, BCGNon-muscle Invasive Bladder Cancer—recruiting
2030-03-29
Estimated 50%
readout ~2030-06-12
Phase 3PF-08634404, Bevacizumab, ChemotherapyIntestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases, Colorectal Neoplasms—recruiting
2030-06-14
Estimated 50%
readout ~2030-08-28
Phase 2/3PF-08634404, Atezolizumab, ChemotherapySmall Cell Lung Cancer (SCLC)—recruiting
2030-06-26
Estimated 50%
readout ~2030-09-09
Phase 3Ritlecitinib higher dose, Ritlecitinib lower doseSevere Alopecia Areata—recruiting
2030-07-31
Estimated 50%
readout ~2030-10-14
Phase 3PF-06741086Hemophilia A, Hemophilia B—recruiting
2030-07-31
Estimated 50%
readout ~2030-10-14
Phase 3Rimegepant (PF-07899801)Acute Treatment of Migraine—recruiting
2030-09-08
Estimated 50%
readout ~2030-10-23
Phase 2EtrasimodColitis, Ulcerative—recruiting
2030-10-18
Estimated 50%
readout ~2031-01-01
Phase 3Elranatamab, Daratumumab, LenalidomideMultiple Myeloma—recruiting
2030-10-24
Estimated 50%
readout ~2031-01-07
Phase 2/3PF-07275315 dose 1, PF-07275315-dose 2, PF-07275315-dose 3Moderate to Severe Chronic Obstructive Pulmonary Disease—recruiting
2030-12-30
Estimated 50%
readout ~2031-03-15
Phase 2/3OsivelotorSickle Cell Disease—recruiting
2031-06-19
Estimated 50%
readout ~2031-08-03
Phase 1/2C. difficile vaccine (previously studied formulation), C. difficile vaccine formulation 1,Clostridoides Difficile Associated Disease—active not recruiting
2031-07-22
Estimated 50%
readout ~2031-10-05
Phase 2/3PF-08634404, Chemotherapy, NivolumabUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma—recruiting
2031-11-29
Estimated 50%
readout ~2032-02-12
Phase 3RimegepantMigraine—recruiting
2032-02-22
Estimated 50%
readout ~2032-05-07
Phase 3AbrocitinibAtopic Dermatitis—recruiting
2033-10-31
Estimated 50%
readout ~2033-12-15
Phase 2Inotuzumab ozogamicin, ALLR3ACUTE LYMPHOBLASTIC LEUKEMIA—recruiting
2040-02-25
Estimated 50%
readout ~2040-05-10
Phase 3Testing of hepatic AAV Vector integrationHemophilia A, Hemophilia B—recruiting

Catalyst news & presentations · 1

Approved drugs (14)

  • HYMPAVZIMARSTACIMAB-HNCQ2024 · Prescription
  • TALZENNATALAZOPARIB TOSYLATE2024 · Prescription
  • VELSIPITYETRASIMOD ARGININE2023 · Prescription
  • ELREXFIOELRANATAMAB2023 · Prescription
  • LITFULORITLECITINIB TOSYLATE2023 · Prescription
  • PAXLOVID (COPACKAGED)NIRMATRELVIR2023 · Prescription
  • ZAVZPRETZAVEGEPANT HYDROCHLORIDE2023 · Prescription
  • BENDAMUSTINE HYDROCHLORIDEBENDAMUSTINE HYDROCHLORIDE2022 · Discontinued
  • PEMETREXED DISODIUMPEMETREXED DISODIUM2022 · Prescription
  • PEMETREXED DITROMETHAMINEPEMETREXED DITROMETHAMINE2022 · Discontinued

Capital structure — dilution & financing

Shares out: 5,699,444,169 · 3 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $29 (+15% upside) · 26 analysts
  • 2026-07-13GuggenheimBuy
  • 2026-07-13BMO CapitalOutperform
  • 2026-07-10B of A SecuritiesNeutral
  • 2026-07-08JP MorganNeutral
  • 2026-07-06Cantor FitzgeraldNeutral
  • 2026-07-06HSBCBuy → Hold

Competitors — Carcinoma

  • LLYELI LILLY & Co$1094.4B · D3
  • JNJJOHNSON & JOHNSON$617.4B · D0
  • ABBVAbbVie Inc.$451.1B · D2
  • MRKMerck & Co., Inc.$318.8B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • ZYMEZymeworks Inc.$1.7B · D1
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • LSTALISATA THERAPEUTICS, INC.$20M · D4
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.